Risks of developing Epstein-Barr virus-related lymphoproliferative disorders after T-cell-depleted marrow transplants

Blood

Volumn 91, Issue 8, 1998, Pages 3079-3083

  Hale, Geoff ^a,b   Waldmann, Herman ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b Therapeutic Antibody Centre   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CYCLOSPORIN A; METHOTREXATE;

ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BONE MARROW TRANSPLANTATION; CHILD; CLINICAL ARTICLE; EPSTEIN BARR VIRUS; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; LYMPHOCYTE DEPLETION; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MALE; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0032522959     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v91.8.3079.3079_3079_3083     Document Type: Article

References (29)

1. Hanto DW, Frizzera G, Purtilo DT, Sakamoto K, Sullivan JL, Saemundsen AK, Klein G, Simmons RL, Najarian JS: Clinical spectrum of lymphoproliferative disorders in renal transplant recipients and evidence for the role of Epstein-Barr virus. Cancer Res 41:4253, 1981
2. Nalesnik MA, Jaffe R, Starzl TE: The pathology of post-transplant lymphoproliferative disorders occurring in the setting of cyclosporin-prednisone immunosuppression. Am J Pathol 133:173, 1988
3. Ho M, Jaffe R, Miller G, Breinig MK, Dummer JS, Makowka L, Atchison RW, Karrer F, Nalesnik MA, Starzl RE: The frequency of Epstein-Barr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestations in children. Transplantation 45:1595, 1988
4. Shapiro RS, McClain K, Frizzera G, Gajil-Peczalska KJ, Kersey JH, Blazar BR, Arthur DC, Patton DF, Greenberg JS, Burke B, Ramsay NKC, McGlave P, Filipovich AH: Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation. Blood 71:1234, 1988
5. Zutter MM, Martin PJ, Sale GE, Shulman HM, Fisher L, Thomas ED, Durnam DM: Epstein-Barr virus lymphoproliferation after bone marrow transplantation. Blood 72:520, 1988
6. Simon M, Bartram CR, Friedrich W, Arnold R, Schmeiser T, Hampl W, Muller-Hermelink HK, Heymer B: Fatal B-cell lymphoproliferative syndrome in allogeneic marrow graft recipients. A clinical immunobiological and pathological study. Virch Arch B Cell Pathol 60:307, 1991
7. Witherspoon RP, Deeg HJ, Storb R: Secondary malignancies after marrow transplantation for leukemia or aplastic anaemia. Transplant Sci 4:33, 1994
8. Caldas C, Ambinder R: Epstein-Barr virus and bone marrow transplantation. Curr Opin Oncol 7:102, 1995
9. Martin PJ, Shulman HM, Schubach WH, Hansen JA, Fefer A, Miller G, Thomas ED: Fatal Epstein-Barr virus associated proliferation of donor B cells after treatment of acute graft-versus-host disease with a murine anti-T cell antibody. Ann Intern Med 101:310, 1984
10. Antin JH, Bierer BE, Smith BR, Ferrara J, Guinan EC, Sieff C, Golan DE, Macklis RM, Tarbell NJ, Lynch E, Reichert TA, Blythman H, Bouloux C, Rappeport JM, Burakoff SJ, Weinstein HJ: Selective depletion of bone marrow T lymphocytes with anti-CD5 monoclonal antibodies: Effective prophylaxis for graft-versus-host disease in patients with hematologic malignancies. Blood 78:2139, 1991
11. Fischer A, Blanche S, Le-Bidois J, Bordigoni P, Gamier JL, Niaudet P, Morinet F, Le Deist F, Fischer AM, Griscelli C, Hirn M: Anti-B-cell monoclonal antibodies in the treatment of severe B cell lymphoproliferative syndrome following bone marrow and organ transplantation. N Engl J Med 324:1451, 1991
12. Gerritsen EJ, Stam ED, Hermans J, van den Berg H, Haraldsson A, van Tol MJ, van den Bergh RL, Waaijer JL, Kroes AC, Kluin PM, Vossen JM: Risk factors for developing EBV related B cell lymphoproliferative disorders BLPD after non-HLA identical BMT in children. Bone Marrow Transplant 18:377, 1996
13. Hanto DW, Frizzera G, Gail-Peczalska KJ, Balfour HH Jr, Simmons RL, Najarian JS: Acyclovir therapy of Epstein-Barr virus-induced post-transplant lymphoproliferative diseases. Transplant Proc 17:89, 1985
14. Shapiro RS, Chauvenet A, McGuire W, Pearson A, Craft AW, McGlave P, Filipovitch A: Treatment of B-cell lymphoproliferative disorders with interferon alpha and intravenous gamma globulin. N Engl J Med 318:1334, 1988
15. Lucas KG, Small TN, Heller G, Dupont B, O'Reilly RJ: The development of cellular immunity to Epstein-Barr virus after allogeneic bone marrow transplantation. Blood 87:2594, 1996
16. O'Reilly RJ, Lacerda JF, Lucas KG, Rosenfield NS, Small TN, Papadopoulos EB: Adoptive cell therapy with donor lymphocytes for EBV-associated lymphomas developing after allogeneic marrow transplants. Important Adv Oncol 149, 1996
17. Schubach WH, Hackman RC, Neiman PE, Miller G, Thomas ED: A monoclonal immunoblastic sarcoma in donor cells bearing Epstein-Barr virus genomes following allogeneic bone marrow grafting for acute lymphoblastic leukemia. Blood 60:180, 1982
18. Savoie A, Perpete C, Carpentier L, Joncas J, Alfieri C: Direct correlation between the load of Epstein-Barr virus-infected lymphocytes in the peripheral blood of pediatric transplant patients and risk of lymphoproliferative disease. Blood 83:2715, 1994
19. Hale G, Waldmann H, for CAMPATH users: Control of graft-versus-host disease and graft rejection by T cell depletion of donor and recipient with CAMPATH-1 antibodies. Results of matched sibling transplants for malignant diseases. Bone Marrow Transplant 13:597, 1994
20. Hale G, Waldmann H, for CAMPATH users: CAMPATH-1 monoclonal antibodies in bone marrow transplantation. Hematotherapy 3:15, 1994
21. Hale G, Waldmann H, for CAMPATH users: Recent results using CAMPATH-1 antibodies to control GvHD and graft rejection. Bone Marrow Transplantation 17:305, 1996
22. Hale G, Waldmann H, Dyer M: Specificity of monoclonal antibody CAMPATH-1 (letter). Bone Marrow Transplant 3:237, 1988
23. Clark RE, Pender N: Transplantation of T-lymphocyte depleted marrow with an addback of T cells. Hematol Oncol 13:219, 1995
24. Naparstek E, Or R, Nagler A, Cividalli G, Engelhard D, Aker M, Gimon Z, Manny N, Sacks T, Tochner Z, Weiss L, Samuel S, Brautbar H, Hale G, Waldmann H, Steinberg SM, Slavin S: T cell depleted allogeneic bone marrow transplantation for acute leukaemia using CAMPATH-1 antibodies and post transplant alloimmunization with donor's peripheral blood lymphocytes for prevention of relapse. Br J Haematol 89:506, 1995
25. Wagemaker G, Heidt PJ, Merchav S, van Bekkum DW: Abrogation of histoincompatibility barriers in rhesus monkeys, in Baum SJ, Ledney GD, Thierfelder S (eds): Experimental Haematology Today. Basel, Switzerland, Karger, 1982, p 111
26. Jabado N, Le Deist F, Cant A, de Graaf-Meeders B, Fasth A, Morgan G, Vellodi A, Bujan W, Hale G, Bujan W, Thomas C, Cavazzano-Calvo M, Wijdenes J, Fischer A: Bone marrow transplantation from genetically HLA-non identical donors in children with fatal inherited disorders excluding severe combined immunodeficiency: Use of two monoclonal antibodies to prevent graft rejection. Paediatrics 98:420, 1996
27. Frame JN, Sheehy D, Cartagena T, Cirrincione C, O'Reilly RJ, Dupont B, Kernan NA: Optimal conditions for in vitro T cell depletion of human bone marrow by Campath-1 plus complement as demonstrated by limiting dilution analysis. Bone Marrow Transplant 4:55, 1989
28. Bunjes D, Theobald M, Wiesneth M, Schrezenmeier H, Hoffmann T, Hertenstein B, Arnold R, Heimpel H: Graft rejection by a population of primed CDw52-host T cells after in vivo/ex vivo T-depleted bone marrow transplantation. Bone Marrow Transplant 12:209, 1993
29. MacKinnon S, Papadopoulos EP, Carabasi MH, Reich L, Collins NH, Boulad F, Castormalaspina H, Childs BH, Gillio AP, Kernan NA, Small TN, Young JW, O'Reilly RJ: Adoptive immunotherapy evaluating escalating dose of donor leukocytes for relapse of chronic myeloid leukaemia following bone marrow transplantation: Separation of graft-versus-leukaemia responses from graft-versus-host disease. Blood 86:1261, 1995